基于临床与遗传风险模型评估R-CHOP后巩固性大剂量化疗在滤泡性淋巴瘤中的价值
该研究纳入431例接受一线R-CHOP的晚期滤泡性淋巴瘤患者,随机接受巩固性HDT/ASCT,并对157例活检组织进行靶向基因分型。结果显示HDT/ASCT未改善总生存,在FLIPI、m7-FLIPI或POD24-PI定义的高危亚组中亦未显著延长无失败生存。
要点
- 巩固性HDT/ASCT未改善未经选择FL患者的总生存。
- FLIPI、m7-FLIPI或POD24-PI高危亚组未从HDT/ASCT显著获益。
- 机器学习预测获益者FFS延长,但OS未达统计学显著。
核心结论
- 一线R-CHOP后巩固性HDT/ASCT未改善未经选择FL患者的总生存,在基因型风险模型定义的亚组中亦未显著改善。
研究设计与样本
- 生存分析纳入431例接受一线R-CHOP的晚期FL患者,随机接受巩固性HDT/ASCT。
- 对157例诊断性活检进行靶向基因分型并计算基因型风险评分。
主要发现
- FLIPI、m7-FLIPI和POD24-PI高危患者分别占27%、18%和22%。
临床怎么用
- 一线R-CHOP后不推荐常规进行巩固性HDT/ASCT。
- 基于FLIPI、m7-FLIPI或POD24-PI的风险分层不足以筛选HDT/ASCT获益人群。
局限性
- 基因分型仅限157例诊断性活检,样本量有限。
- 机器学习预测获益的亚组分析为探索性,OS未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose therapy and autologous stem cell transplantation (HDT/ASCT) is an effective salvage treatment for eligible patients with follicular lymphoma (FL) and early progression of disease (POD). Since the introduction of rituximab, HDT/ASCT is no longer recommended in first remission. We here explored whether consolidative HDT/ASCT improved survival in defined subgroups of previously untreated patients. We report survival analyses of 431 patients who received frontline rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for advanced FL, and were randomized to receive consolidative HDT/ASCT. We performed targeted genotyping of 157 diagnostic biopsies, and calculated genotype-based risk scores. HDT/ASCT improved failure-free survival (FFS; hazard ratio [HR], 0.8, P = .07; as-treated: HR, 0.7, P = .04), but not overall survival (OS; HR, 1.3, P = .27; as-treated: HR, 1.4, P = .13). High-risk cohorts identified by FL International Prognostic Index (FLIPI), and the clinicogenetic risk models m7-FLIPI and POD within 24 months-prognostic index (POD24-PI) comprised 27%, 18%, and 22% of patients. HDT/ASCT did not significantly prolong FFS in high-risk patients as defined by FLIPI (HR, 0.9; P = .56), m7-FLIPI (HR, 0.9; P = .91), and POD24-PI (HR, 0.8; P = .60). Similarly, OS was not significantly improved. Finally, we used a machine-learning approach to predict benefit from HDT/ASCT by genotypes. Patients predicted to benefit from HDT/ASCT had longer FFS with HDT/ASCT (HR, 0.4; P = .03), but OS did not reach statistical significance. Thus, consolidative HDT/ASCT after frontline R-CHOP did not improve OS in unselected FL patients and subgroups selected by genotype-based risk models.
引用
- Alig S, Jurinovic V, Shahrokh Esfahani M, et al. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Adv. 2020. PMID: 32941649. doi:10.1182/bloodadvances.2020002546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。